FindTrial
Sign In

Long-Term Follow-up of Fabry Disease Subjects who were Treated with ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-512700-18-00
Acronym
ST-920-LT01
Enrollment
1
Registered
2025-01-31
Start date
2025-04-03
Completion date
Unknown
Last updated
2025-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fabry Disease (X-linked lysosomal storage disease).

Brief summary

To evaluate long-term safety of ST-920 by assessment of incidence and severity of adverse events (AEs)

Interventions

DRUGST-920

Sponsors

Sangamo Therapeutics Inc.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
Male
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
To evaluate long-term safety of ST-920 by assessment of incidence and severity of adverse events (AEs)—

Countries

Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026